Synthego Raises $200 Million To Accelerate The Field Of Crispr-Based Medicines From Early-Phase Research To The Clinic
Synthego Raises $200 Million To Accelerate The Field Of Crispr-Based Medicines From Early-Phase Research To The Clinic
02/17/22, 8:00 AM
Money raised
$200 million
Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors. Also participating in the round were new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi and existing investors Wellington Management, RA Capital Management and Moore Strategic Ventures. The company also recently appointed Avi Raval as chief financial officer.
Company Info
Additional Info
Synthego was founded to revolutionize genome engineering technology, helping translate genomics into the clinic and ultimately making engineered biological therapies accessible to all patients. The company leverages machine learning, automation and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company's platforms vertically integrate proprietary hardware, software, bioinformatics, chemistries and molecular biology to advance both basic research and therapeutic development programs. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale. For more information on Synthego, please visit the company's website at www.Synthego.com.
SOURCE Synthego